A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).

被引：0
|
作者：
Gruenwald, Viktor
Bauer, Sebastian
Hermes, Barbara
Ivanyi, Philipp
Lindner, Lars H.
Pink, Daniel
Reichardt, Peter
Richter, Stephan
Tuchscherer, Armin
机构：
[1] Hannover Med Sch, Dept Hematol Hemostaseol Oncol & Stem Cell Transp, Hannover, Germany
[2] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[3] Univ Klinikum Tubingen, Tubingen, Germany
[4] Ludwig Maximilians Univ Munchen, Univ Hosp, Munich, Germany
[5] Helios Klinikum Bad Saarow, Bad Saarow Pieskow, Germany
[6] HELIOS Klinikum Berlin Buch, Berlin, Germany
[7] Univ Hosp Carl Gustav Carus, Dresden, Germany
[8] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS11075
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma:: a study by the EORTC Soft Tissue and Bone Sarcoma Group
    Judson, I
    Radford, JA
    Harris, M
    Blay, JY
    van Hoesel, Q
    le Cesne, A
    van Oosterom, AT
    Clemons, MJ
    Kamby, C
    Hermans, C
    Whittaker, J
    di Paola, ED
    Verweij, J
    Nielsen, S
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (07) : 870 - 877
  • [22] Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma
    Livingston, Michael B.
    Jagosky, Megan H.
    Robinson, Myra M.
    Ahrens, William A.
    Benbow, Jennifer H.
    Farhangfar, Carol J.
    Foureau, David M.
    Maxwell, Deirdre M.
    Baldrige, Emily A.
    Begic, Xhevahire
    Symanowski, James T.
    Steuerwald, Nury M.
    Anderson, Colin J.
    Patt, Joshua C.
    Kneisl, Jeffrey S.
    Kim, Edward S.
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6424 - 6431
  • [23] EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).
    Gruenwald, Viktor
    Kunitz, Annegret
    Schuler, Markus Kajo
    Kopp, Hans-Georg
    Kasper, Bernd
    Lindner, Lars
    Chemnitz, Jens-Marcus
    Stein, Alexander
    Schoeffski, Patrick
    Steffen, Bjoern
    Bauer, Sebastian
    Egerer, Gerlinde
    Kneba, Michael
    Crysandt, Martina
    Koch, Armin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
    Loong, Herbert H. F.
    Blackstein, Martin E.
    Gupta, Abha A.
    Hogg, David
    Mackay, Helen
    Dhani, Neesha C.
    Oza, Amit M.
    Moore, Malcolm J.
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
    Loong, Herbert H. F.
    Blackstein, Martin E.
    Gupta, Abha A.
    Hogg, David
    Culala, Lindsay
    Nyquist-Schultz, Kjirsten
    Baker, Stephanie
    Wang, Lisa
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Combination of Pegylated Liposomal Doxorubicin (PLD) and ifosfamide (IFO) in patients with advanced soft tissue sarcoma (STS). A phase II study of the Hellenic Cooperative Oncology Group
    Bafaloukos, Dimitrios
    Kosmidis, Paris
    Briasoulis, Evangelos
    Gogas, Helen
    Aravantinos, Gerasimos
    Papadimitriou, Christos
    Economopoulos, Theofanis
    Papakostas, Pavlos
    Fountzilas, George
    ANNALS OF ONCOLOGY, 2004, 15 : 198 - 198
  • [27] Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
    Somaiah, Neeta
    Conley, Anthony P.
    Parra, Edwin Roger
    Lin, Heather
    Amini, Behrang
    Soto, Luisa Solis
    Salazar, Ruth
    Barreto, Carmelia
    Chen, Honglei
    Gite, Swati
    Haymaker, Cara
    Nassif, Elise F.
    Bernatchez, Chantale
    Mitra, Akash
    Livingston, John Andrew
    Ravi, Vinod
    Araujo, Dejka M.
    Benjamin, Robert
    Patel, Shreyaskumar
    Zarzour, Maria A.
    Sabir, Sharjeel
    Lazar, Alexander J.
    Wang, Wei-Lien
    Daw, Najat C.
    Zhou, Xiao
    Roland, Christina L.
    Cooper, Zachary A.
    Rodriguez-Canales, Jaime
    Futreal, Andrew
    Soria, Jean-Charles
    Wistuba, Ignacio I.
    Hwu, Patrick
    LANCET ONCOLOGY, 2022, 23 (09): : 1156 - 1166
  • [28] Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS).
    Morgan, JA
    George, S
    Desai, J
    Amand, MS
    Horton, D
    Wilkins, E
    Manola, J
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 820S - 820S
  • [29] Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS)
    Keohan, M.
    D'Adamo, D.
    Qin, L.
    Saulle, M.
    Caltieri, L.
    Schuetze, S.
    Wright, J. J.
    Schwartz, G.
    Maki, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma
    Ha, Huan T.
    Griffith, Kent A.
    Zalupski, Mark M.
    Schuetze, Scott M.
    Thomas, Dafydd G.
    Lucas, David R.
    Baker, Laurence H.
    Chugh, Rashmi
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (01): : 77 - 82
12345